SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Icodec cleared the phase III trials. (Tim de Waele
Business
Novo Nordisk Brokers Another Deal in Fight Against Obesity
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
January 17, 2022
 · 
3 min read
 · 
Kate Goodwin
Genetown
New Evidence Adamently Suggests Epstein-Barr Virus Triggers MS
New research from Harvard University strongly suggests that infection with the Epstein-Barr virus is the leading cause of multiple sclerosis in most patients.
January 14, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
Immunotherapy Shows Promise in Phase II on Tough T1D Path
Imcyse’s peptides work by priming cytolytic T cells to recognize and destroy those immune cells attacking the pancreas beta cells.
January 13, 2022
 · 
2 min read
 · 
Kate Goodwin
Mindy Schauer/MediaNewsGroup/Orange County Registe
Business
Xenotransplant Advocates Rejoice as a Pig’s Heart Beats in Man’s Chest
Gene editing has broken through to a new level as a Maryland man recovers from surgery in which a heart from a genetically modified pig may save his life.
January 11, 2022
 · 
3 min read
 · 
Kate Goodwin
Dan Kitwood/Getty Images
Business
Pfizer Triple-Partners for Future mRNA Vaccines and Genetic Medicines
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
January 10, 2022
 · 
2 min read
 · 
Kate Goodwin
MikeDotta / Shutterstock
Genetown
Study Finds Link Between Senescent Cells and Down Syndrome
A research team out of MIT may have found a surprising causal aspect of Down syndrome that’s worth further investigation.
January 7, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
ONK Snags $21.5 Million for Natural Killer Cell Therapies
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
January 6, 2022
 · 
2 min read
 · 
Kate Goodwin
BioMidwest
Money on the Move: December 29 – January 4
Here’s who rang in the New Year by joining the NASDAQ or raising private equity funds.
January 4, 2022
 · 
2 min read
 · 
Kate Goodwin
Biotech Beach
Study: Men More Likely to Experience Damaging Antibodies after COVID-19 Illness
While women are more statistically susceptible to autoimmune diseases, the research found that men with at least a mild COVID-19 infection had far more autoantibody (AAB) reactivity.
January 4, 2022
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Jer123/Getty Images
Business
Kyverna Tries NIH Cell Therapy for Autoimmune Disease
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
January 3, 2022
 · 
2 min read
 · 
Kate Goodwin
Courtesy Niels Wenstedt/BSR Agency via Getty Image
Business
Janssen Cuts Ties with Theravance After IBD Program Flop
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
December 23, 2021
 · 
2 min read
 · 
Kate Goodwin
Money on the Move: December 15 – 21
These biotech companies made the nice list, earning them far more than a lump of coal.
December 22, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Omicron Overtakes Delta as Dominant Strain for New COVID Infection
In the last week, Omicron is credited for 73% of new COVID-19 infections and is accounted for 12.6% of positive cases, making it the most rapidly spreading variant the country has seen yet.
December 21, 2021
 · 
2 min read
 · 
Kate Goodwin
Sarah Silbiger/Getty Images
FDA
Schizophrenia Drug CAPLYTA Snags Second Approval for Bipolar Depression
On Monday, Intra-Cellular Therapies announced that the FDA has approved CAPLYTA to treat the deep depressive episodes of patients with bipolar I or II.
December 20, 2021
 · 
2 min read
 · 
Kate Goodwin
This Year’s Flu Vaccine a “Major Mismatch” to Prevalent Strain
Another flu season, another less than effective flu vaccine. The shape-shifting virus has mutated already and this year’s flu vaccine is a poor match to fight it.
December 17, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More